The proposed investigation was carried out to evaluate the antihyperglycemic potential and to explore the structureactivity relationship (SAR) of a series of 28 hybrid sulfonylurea-linked chalconoids using streptozotocin-induced type 2 diabetic rats. Among all the compounds tested, compound SC 21 exhibited remarkable antidiabetic activity.
INTRODUCTION
Drug discovery is a continuous process which, depending on the strategy used, typically comprises several discrete stages: target identification and validation; assay development; screening (whole cell or molecular target-based) to identify hits; procurement/synthesis and assessment of analogues to develop structure-activity relationships (SAR) and identify leads; iterative medicinal chemistry to optimize leads; and preclinical development prior to clinical evaluation 1 . Diabetes defines a group of metabolic diseases categorized by hyperglycemia and pancreatic β-cell dysfunction. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by high blood sugar levels resulting from the reduction of insulin secretion and/or insulin resistance 2 . It is widely known that elevation of blood glucose caused by disruption of carbohydrate, protein and fat metabolism can lead to diabetic complications in several organs and tissues, including eyes, kidneys, nerves and blood vessels 3 . Although various clinically used antidiabetic drugs are available, it has been shown that current clinical management is not adequately addressed by existing therapies, and therefore an exploration of the novel scaffolds as antidiabetic agents are still in demand 4 . The search for new drugs with antidiabetic activity remains a focused area of worldwide research. Chalcones are naturally occurring bichromophoric compounds captivated significant attention due to its diverse range of pharmacological properties such as heat shock protein-inducer 5 22 , cytotoxic 23 , anticancer 24 , and anti-prostatic 25 . Similarly sulfonylurea moiety has also gained privileged status due to its biological activity profiles which includes hypoglycemic 26 , peroxisome proliferator-activated receptor γ agonistic 27 , antimicrobial 28 , herbicidal 29 , selective EP4 receptor antagonists 30 , selective bombesin receptor subtype-3 (SCS-3) agonist 31 , antagonists of the CXCR2 receptor 32 , antimalarial 33 , Vibrio fischeri quorum sensing regulator 34 , selective antagonists of the TPα and
TPβ isoforms of the human thromboxane A2 receptor 35 , reversible inhibitors of human steroid sulfatase 36 , KATP-channel openers 37 , antagonists of the ANG II AT1 receptors 38 , inhibitors of Acyl-CoA: cholesterol O-Acyltransferase 39 , inhibitors of aldehyde dehydrogenase 40 , non-competitive Inhibitor of acetohydroxyacid synthase from Mycobacterium tuberculosis 41 , cancer chemotherapeutic 42 , antitumor 43 , oncolytic 44 , diuretic 45 , selective β3 adrenergic receptor agonist 46 , and vasodilator 47 . Therefore, a series of novel hybrid sulfonylurea-linked chalconoids (SC1-28) were designed, synthesized, characterized and earlier reported from our laboratories as potential cytotoxic and antimicrobial agents 48 . It is proved from the literature that the compounds containing neither sulfonylurea nor chalcone moieties often shows significant antidiabetic activity profiles.
EXPERIMENTAL
In the present investigation, a series of novel hybrid sulfonylurea-linked chalconoids (SC1-28) 48 shown in (Fig.-1) were evaluated them for in vivo antihyperglycemic potential using streptozotocin-induced type 2 diabetic rats 49 . The experimental protocol has been approved by the Institutional Animal Ethics Committee (IAEC) and by the Animal Regulatory Body of the Government. (Regd. No. 516/01/A/CPCSEA). The direct comparison of the antihyperglycemic effect of the sulfonylurea-linked chalcones SC1-28 is made rather difficult by the fact that not only the maximal decrease of the blood glucose level produced by the standard doses of the compound but also the dose-response curves vary from compound to compound. 
RESULTS AND DISCUSSION
The results of in vivo antihyperglycemic activity of the synthesized sulfonylurea-linked chalcones (SC1-28) showed that all the compounds were found to possess moderate to potential ability to reduce blood glucose levels in streptozotocin-induced type 2 diabetic rats. We consequently found that the blood glucose reduction ability of the titled compounds (SC1-28) was followed a dose-dependent manner in their antihyperglycemic activity. Among all the tested compounds, compound SC21 (Fig.-2 It is noteworthy to establish the structure-activity relationships (SARs) for the observed antihyperglycemic activity of sulfonylurea-linked chalcones SC1-28. It is clear from the results of antihyperglycemic activity that the structural requirements for retaining (or enhancing) antihyperglycemic property in sulfonylurea-linked chalcones SC1-28 are not inflexible. As such, the following are the conventional SARs. The α,β-unsaturated ketone and sulfonylurea-linker moieties are the vital structural pharmacophores for maintaining the antihyperglycemic activity. It is remarkable that an enhanced level of activity was observed when the phenyl ring of α,β-unsaturated carbonyl system is substituted with different functional groups and decreased by some other substituents. The order of activity was SC5 (4- respectively. An ortho and para substitution on the phenyl ring of α,β-unsaturated carbonyl system with less electronegative halogens compared to fluorine, such as chloro may significantly enhance the activity as seen in the case of compound SC21. A para-substitution on the phenyl ring of α,β-unsaturated carbonyl system with electron-donating groups possibly will increase the activity. A para-substitution on the phenyl ring of α,β-unsaturated carbonyl system with hydroxyl group relevant for maintaining activity. The replacement of phenyl ring with a pyridine-4-yl ring as in compound SC27 exhibited a significant increase in activity compared to the compounds possessing other aromatic or heteroaromatic ring systems, the order of activity was SC26 (pyridin-3-yl) > SC25 (pyrrole) > SC28 (anthracen-9-yl), respectively.
CONCLUSION
In summary, we have evaluated a series of sulfonylurea-linked chalconoids and among the compounds tested α,β-unsaturated carbonyl system and sulfonylurea moieties were appeared to be pivotal to retain the antihyperglycemic potential of this chemotype. This study would be the remarkable implications to develop new hybrid scaffolds consisting of either chalcone or sulfonylurea chemical pharmacophores in their basic nucleus.
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